Latest Articles
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - Medical Xpress
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer Medical Xpress
Published: June 1, 2026, 8 p.m.
FOCL: Robotic focal therapy platform drives rapid growth, clinical adoption, and expansion into new indications - TradingView
FOCL: Robotic focal therapy platform drives rapid growth, clinical adoption, and expansion into new indications TradingView
Published: June 1, 2026, 6:25 p.m.
FOCL: Robotic focal therapy drives rapid growth, expanding into new indications and global markets - TradingView
FOCL: Robotic focal therapy drives rapid growth, expanding into new indications and global markets TradingView
Published: June 1, 2026, 4:35 p.m.
Dostarlimab Plus Chemo May Offer Cure to Some Advanced Endometrial Cancer Patients - Cancer Therapy Advisor
Dostarlimab Plus Chemo May Offer Cure to Some Advanced Endometrial Cancer Patients Cancer Therapy Advisor
Published: May 30, 2026, 4 a.m.
Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients - News-Medical
Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients News-Medical
Published: May 30, 2026, 2:16 a.m.
Pembrolizumab Plus Chemotherapy Shows Sustained Survival in Advanced EC - CancerNetwork
Pembrolizumab Plus Chemotherapy Shows Sustained Survival in Advanced EC CancerNetwork
Published: May 30, 2026, 12:40 a.m.
Pembrolizumab Plus Chemotherapy Shows Long-Term OS Benefit in Advanced/Recurrent Endometrial Cancer - OncLive
Pembrolizumab Plus Chemotherapy Shows Long-Term OS Benefit in Advanced/Recurrent Endometrial Cancer OncLive
Published: May 29, 2026, 11:57 p.m.
Immunotherapy Addition Demonstrates Sustained Survival Benefits in - Bioengineer.org
Immunotherapy Addition Demonstrates Sustained Survival Benefits in Bioengineer.org
Published: May 29, 2026, 11:56 p.m.
Dostarlimab Plus Chemotherapy Yields Curative Potential in dMMR/MSI-H Endometrial Cancer - CancerNetwork
Dostarlimab Plus Chemotherapy Yields Curative Potential in dMMR/MSI-H Endometrial Cancer CancerNetwork
Published: May 29, 2026, 10:40 p.m.
mRNA Therapy Offers Hope for Uterine Factor Infertility - Technology Networks
mRNA Therapy Offers Hope for Uterine Factor Infertility Technology Networks
Published: May 28, 2026, 2:57 p.m.
Link copied to clipboard!